三阳性乳腺癌的强化辅助治疗方案选择

Selection of Intensive Adjuvant Therapy for Triple-positive Breast Cancer

三阳性乳腺癌(triple-positive breast cancer,TPBC)是以激素受体(hormonereceptor,HR)阳性(HR+)和人类表皮生长因子受体(humanepidermalgrowthfactorreceptor 2,HER2)阳性(HER2+)共表达的一类特殊类型的乳腺癌。因其同时受HR信号通路和HER2信号通路共同调控影响,TPBC的治疗策略选择一直是临床关注的热点。TPBC患者强化辅助治疗选择不一,序贯、联合,内分泌治疗和靶向治疗如何精准的谋局落子,尚缺少系统性理论的支持。综述查阅了PUBMED、美国临床试验数据库(ClinicalTrials.gov)、知网等,梳理出近年来TPBC治疗方面的11项随机对照试验结果,为TPBC的辅助强化治疗策略的选择提供临床参考依据。

Triple-positive breast cancer(TPBC)is a special type of breast cancer characterized by the co-expression of hormone receptors(HR+)and human epidermal growth factor receptor 2(HER2+).Due to the regulation of the HR signaling pathway and the HER2 signaling pathway,the treatment strategy for TPBC has been a hot topic of clinical attention.There is currently a lack of systematic theoretical support for the selection of intensive adjuvant therapy for TPBC patients,including sequential or combination therapy,endocrine therapy,and targeted therapy.This review article examines 11 randomized controlled trials on TPBC treatment in recent years,obtained from database such as PUBMED,ClinicalTrials.gov,and CNKI,in order to provide clinical reference for the selection of neoadjuvant therapy strategies for TPBC.